Trends in Infectious Diseases: Updates on Treatment & Prevention Strategies for HIV and HCVRapid Start ART — A New Model for HIV Care
RAPID ART: high virologic suppression rates with immediate ART initiation in a vulnerable urban clinic population.
Coffey S, et al. AIDS. 2018. [Epub ahead of print]
Cohen MS, et al. N Engl J Med. 2016;375(9):830-839.
Cohen MS, et al. N Engl J Med. 2011;365(6):493-505.
Colasanti J, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI) 2018; March 4−7, 2018; Boston, MA. Poster 1109.
Continuous retention and viral suppression provide further insights into the HIV care continuum compared to the cross-sectional HIV care cascade.
Colasanti J, et al. Clin Infect Dis. 2016;62(5):648-654.
Eisinger RW, et al. JAMA. 2019;321(5):451-452.
Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans.
Halperin J, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
Schoen J, Gallagher G. Healio Infect Dis News. 2018.
INSIGHT START Study Group. N Engl J Med. 2015;373(9):795-807.
Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial.
Koenig SP, et al. PLoS Med. 2017;14(7):e1002357.
Effect of offering same-day ART vs usual health facility referral during home-based HIV testing on linkage to care and viral suppression among adults with HIV in Lesotho: the CASCADE randomized clinical trial.
Labhardt ND, et al. JAMA. 2018;319(11):1103-1112.
Association of implementation of a universal testing and treatment intervention with HIV diagnosis, receipt of antiretroviral therapy, and viral suppression in East Africa.
Petersen M, et al. JAMA. 2017;317(21):2196-2206.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a U.S. public health setting.
Pilcher CD, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial.
Rosen S, et al. PLoS Med. 2016;13(5):e1002015.
Scheer S, et al. Clin Infect Dis. 2018;66(7):1027-1034.
TEMPRANO ANRS 12136 Study Group. N Engl J Med. 2015;373(9):808-822.
White K, et al. CROI 2018. March 4−7, 2018; Boston, MA. Abstract 532.
The CDC is a division within the US Department of Health and Human Services (DHHS), the principal agency for protecting the health of all Americans. This comprehensive site provides extensive links to topics across the HIV-care continuum, including PrEP.
Smartphone Pill-Reminder Apps (Free)
Rapid Start ART — A New Model for HIV Care
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
The Emerging Role of the Diabetologist
Key Issues Impacting OB/GYN Practice
An Interactive Experience Highlighting Recent Clinical Advances
Hot Topics in HBV, HCV, and NASH
Emerging Concepts in Patient Management
Building Your Understanding to Combat a Growing Problem
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Understanding the Growing Syndemic — Opioids, HCV, and HIV
Appraising the Therapeutic Armamentarium in Moderate and Severe Disease
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
An Interactive Learning Experience
A Focus on Clinical Evidence and Guideline Recommendations
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
Volume 1: A Guided Tour of the Evidence Driving Selection of First-line Advanced Therapies in Moderate to Severe IBD
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
A “How To” Series Spanning Policy to Practice
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care